According to Aegis Therapeutics, the company has been granted US Patent No. 8,440,631 for fast-acting formulations of triptans for the treatment of migraines. The patent is the second for Aegis’s triptan nasal sprays using its Intravail transmucosal absorption enhancers; the company got the first patent in September 2012. Clinical trials have demonstrated that Intravail sumatriptan reaches therapeutic levels in the blood 20-30 times faster than currently marketed sumatriptan nasal sprays, the company says.
Aegis now has more than 50 patents either issued or pending, including US patents for intranasal delivery of parathyroid hormone and GLP-1 peptide analogs.
Read the Aegis press release.
